Medulloblastoma (MB) is the most common CNS embryonal tumor. While the overall cure rate is around 70%, patients with high-risk disease continue to have poor outcome and experience long-term morbidity. MB is among the tumors for which diagnosis, risk stratification, and clinical management has shown the most rapid advancement. These advances are largely due to technological improvements in diagnosis and risk stratification which now integrate histomorphologic classification and molecular classification. MB stands as a prototype for other solid tumors in how to effectively integrate morphology and genomic data to stratify clinicopathologic risk and aid design of innovative clinical trials for precision medicine. This review explores the current diagnostic and classification of MB in modern neuropathology laboratories.

中文翻译：

---

髓母细胞瘤的病理，诊断和分类。

髓母细胞瘤（MB）是最常见的中枢神经系统胚胎性肿瘤。虽然总治愈率约为70％，但高危疾病患者的预后仍然很差，并且长期发病。MB是诊断，风险分层和临床管理进展最快的肿瘤之一。这些进展很大程度上归因于诊断和风险分层的技术进步，这些技术现已将组织形态学分类和分子分类结合在一起。MB是其他实体瘤的原型，可用于如何有效地整合形态学和基因组数据以分层临床病理风险并帮助设计精确医学的创新性临床试验。这篇综述探讨了现代神经病理学实验室中甲基溴的当前诊断和分类。